Clinical Trial Update: Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing valganciclovir prophylaxis versus preemptive therapy for cytomegalovirus infection in living donor kidney transplant recipients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Valcyte (valganciclovir) (valganciclovir)

Snippet

Sponsor: University of Guadalajara | Conditions: Cytomegalovirus Infections | Phase 4 | Status: ACTIVE_NOT_RECRUITING